GlassScriptPhysician profile
Gerald B Broussard
NPI 1073511903
$2,075.90
in general payments reported to CMS, 2019-2025
17 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $221 · 2021: $116 · 2022: $297 · 2023: $166 · 2024: $463 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.57 | 2022-2025 | Durysta, Lumigan |
| Allergan, INC. | $341.71 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $304.65 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $165.84 | 2022-2025 | Acthar |
| Alcon Vision LLC | $145.15 | 2019-2025 | Rocklatan |
| Biotissue Holdings INC. | $133.73 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $58.28 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $48.07 | 2023 | |
| Astellas Pharma US INC | $44.28 | 2023-2024 | Izervay |
| Johnson & Johnson Surgical Vision, INC. | $32.47 | 2019 | |
| Oyster Point Pharma, INC. | $30.02 | 2024 | Tyrvaya |
| Amgen INC. | $19.93 | 2025 | Tepezza |
| Bausch & Lomb Americas INC. | $19.77 | 2024 | Xiidra, Miebo |
| Rayner Intraocular Lenses Limited | $18.72 | 2022 | |
| Rxsight INC | $17.49 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $17.02 | 2024 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $16.20 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Broussard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.